Edwards Lifesciences (EW) Return on Capital Employed (2010 - 2026)

Edwards Lifesciences' Return on Capital Employed history runs 17 years deep, the most recent figure standing at 11.13% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 110.0% year-over-year to 11.13% in Q1 2026; TTM through Mar 2026 was 11.13%, a 110.0% decrease from a year earlier, with the FY2025 full-year figure at 10.93%, down 327.0% from the prior year.
• Return on Capital Employed grew to 11.13% in Q1 2026 per EW's latest filing, from 10.83% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 23.24% in Q1 2022 and bottomed at 10.83% in Q4 2025.
• The 5-year median for Return on Capital Employed is 15.7% (2024), against an average of 16.07%.
• Across the five-year window, Return on Capital Employed jumped 888 bps in 2022 and plunged 671 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 20.13% in 2022, then declined by 17 bps to 16.7% in 2023, then dropped by 28 bps to 11.98% in 2024, then dropped by 10 bps to 10.83% in 2025, then advanced by 3 bps to 11.13% in 2026.
• Per Business Quant, the three latest EW Return on Capital Employed figures stand at 11.13% (Q1 2026), 10.83% (Q4 2025), and 12.09% (Q3 2025).